Phil competitors

Highly adept, results-driven operations executive with broad based expertise leading people. Ambitious, solutions-focused leader experienced in developing strategies that convert technology to revenue, raising capital, and executing initiatives in time-critical circumstances. Distinguished professional that has successfully built and led cross functional management teams and developed and integrated overlapping strategies. Consummate director that thrives working in midsize and start-up commercial settings in global, domestic and international environments. SUMMARY ► Engaging leader possessing a winning blend of entrepreneurial drive, strategic talent, and communications acumen. Skilled in managing large, complex projects to produce exemplary results, via hands-on involvement and cross-functional delegation. ► Leverages a unique mix of visionary, strategic, operations and analytical expertise, consistently exceeding performance goals by aligning talents and effort with organizational objectives. An influential leader who creates immediate impact, produces results and fuels excellence and innovation. LEADERSHIP HIGHLIGHTS ★ Co-founded an intellectual property accelerator to help inventors commercialize technologies in the Life Science and Healthcare verticals, working with partners with extensive leadership expertise in the Pharmaceutical and Life Science markets. ★ Prior successes include executive roles as CCO at Quant HC, Vice President of Business Development at Takeda USA, and Sr. Director of Sales and Marketing for Takeda Canada. Specialties: Strategy, Commercialization, Development, Sales and Marketing, Business Development Performance Management, Product Development, wide and varied Healthcare Industry,

Mike Derkacz is a Board Member at Braeburn, Treasurer at Natl Pharmaceutical Council, and President/CEO at Braeburn. He has worked as VP & Gen Mgr:CNS Business Unit at Teva Pharmaceutical Indus Ltd and Senior VP/Head:CNS at Teva Pharmaceutical Indus Ltd.

Michael Kope is Co-Founder and Co-CEO of Underdog Pharmaceuticals, a company whose mission is to treat the underlying causes of age-related disease. Underdog Pharmaceuticals develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration. Mr. Kope was also Founding CEO of SENS Research Foundation, a non-profit that is redefining the way the world researches and treats age-related ill health, while inspiring the next generation of biomedical scientists. Mr. Kope received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel; as Director of Corporate Development for Aviron, and for MedImmune, Inc.; and as CEO and officer of a number of start-ups in the biotechnology space. He specializes in business development and consulting, and is widely experienced with biotechnology organizations. Mike has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, and facilitated a number of successful startups.